CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 401 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $45,530 | -7.2% | 843 | +17.1% | 0.02% | -7.7% |
| Q1 2024 | $49,075 | +56.8% | 720 | +44.0% | 0.03% | +44.4% |
| Q4 2023 | $31,300 | +37.9% | 500 | 0.0% | 0.02% | +20.0% |
| Q3 2023 | $22,695 | +0.4% | 500 | 0.0% | 0.02% | 0.0% |
| Q1 2023 | $22,615 | +11.3% | 500 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $20,325 | -38.4% | 500 | 0.0% | 0.02% | -44.4% |
| Q3 2022 | $33,000 | +10.0% | 500 | 0.0% | 0.03% | +17.4% |
| Q2 2022 | $30,000 | -3.2% | 500 | 0.0% | 0.02% | +21.1% |
| Q1 2022 | $31,000 | -18.4% | 500 | 0.0% | 0.02% | -13.6% |
| Q4 2021 | $38,000 | -32.1% | 500 | 0.0% | 0.02% | -35.3% |
| Q3 2021 | $56,000 | -30.9% | 500 | 0.0% | 0.03% | -32.0% |
| Q2 2021 | $81,000 | +575.0% | 500 | +400.0% | 0.05% | +525.0% |
| Q1 2021 | $12,000 | – | 100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |